Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELDN 
Eledon Pharmaceuticals Inc (ELDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ELDN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.25% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 153.90M USD | Price to earnings Ratio 3.95 | 1Y Target Price 9.5 |
Price to earnings Ratio 3.95 | 1Y Target Price 9.5 | ||
Volume (30-day avg) 6 | Beta -0.14 | 52 Weeks Range 2.38 - 5.54 | Updated Date 08/29/2025 |
52 Weeks Range 2.38 - 5.54 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.65 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.22 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.4% | Return on Equity (TTM) 30.03% |
Valuation
Trailing PE 3.95 | Forward PE 5.39 | Enterprise Value 47129161 | Price to Sales(TTM) - |
Enterprise Value 47129161 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.84 | Shares Outstanding 59881800 | Shares Floating 46043696 |
Shares Outstanding 59881800 | Shares Floating 46043696 | ||
Percent Insiders 1.4 | Percent Institutions 72.25 |
Upturn AI SWOT
Eledon Pharmaceuticals Inc
Company Overview
History and Background
Eledon Pharmaceuticals, formerly known as Tolerion, was founded with a focus on developing treatments for autoimmune and inflammatory diseases. The company's name was changed to Eledon in 2020. Their main focus is on therapies for organ and cellular transplantation.
Core Business Areas
- Biopharmaceutical Development: Focuses on research and development of novel therapeutics for autoimmune and inflammatory diseases, including those related to organ transplantation.
Leadership and Structure
Key leaders include the CEO, CFO, and Chief Medical Officer. The organizational structure reflects a typical biotech company with departments focused on R&D, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- TOL101: TOL101 is Eledon's lead product candidate, a recombinant IL-15 receptor antagonist being developed for prevention of acute Graft-versus-Host Disease (GvHD) and other inflammatory conditions. As it is still in development, there is no current market share or revenue. Competitors in the GvHD space include Kadmon (KDMN, acquired by Sanofi), Incyte (INCY), and potential future therapies from other biopharmaceutical companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and significant competition. The market for autoimmune and inflammatory disease treatments is large and growing.
Positioning
Eledon is positioned as an emerging biopharmaceutical company focused on innovative therapies. Its competitive advantage lies in its novel approach to targeting IL-15, a key cytokine in inflammation and immunity.
Total Addressable Market (TAM)
The TAM for GvHD treatment is estimated to be in the billions of dollars. Eledon is positioning itself to capture a share of this market with TOL101, assuming successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (IL-15 antagonism)
- Strong scientific team
- Focus on unmet medical needs
- Potential for first-in-class therapy
Weaknesses
- Dependence on single lead product candidate
- Limited financial resources
- High risk of clinical trial failure
- Lack of commercialization experience
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Breakthrough Therapy Designation
Threats
- Clinical trial failure
- Regulatory hurdles
- Competition from established players
- Patent challenges
Competitors and Market Share
Key Competitors
- INCY
- SNY
Competitive Landscape
Eledon faces intense competition from established pharmaceutical companies with larger resources and approved products. Eledon's advantage depends on demonstrating superior efficacy and safety of TOL101.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, as the company is in the development phase.
Future Projections: Future growth is contingent on successful clinical trials and regulatory approval of TOL101. Analyst projections vary widely based on different assumptions about clinical and regulatory success.
Recent Initiatives: Recent initiatives include advancing TOL101 through clinical trials, exploring new indications, and seeking partnerships.
Summary
Eledon Pharmaceuticals is a high-risk, high-reward development-stage biopharmaceutical company. Its success hinges on the clinical trial results of TOL101. They need to secure funding and strategic partnerships to navigate the competitive landscape and regulatory hurdles. Positive clinical data will be the main driver of shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Analyst reports
- Industry databases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may be subject to change. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eledon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2014-09-17 | CEO & Non Independent Director Dr. David-Alexandre C. Gros M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://eledon.com |
Full time employees 31 | Website https://eledon.com | ||
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.